COMMUNIQUÉS West-GlobeNewswire

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
06/01/2026
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding of live [...]
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
06/01/2026
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR [...]
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44 th Annual J.P. Morgan Healthcare Conference in [...]
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, [...]
NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
Aarhus, Denmark, 6 January 2026 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that Thomas Holm [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/01/2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired [...]
MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI
06/01/2026
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated 10.3% mean weight reduction at Week 24 with a best-in-class safety [...]
SurgiBox Inc. Appoints Kelly Laurel as Chief Executive Officer
06/01/2026
Current COO to Lead First-of-its-Kind Medical Device Company into Next Phase of Global Growth and Expansion CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SurgiBox Inc., the medical technology company transforming [...]
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies
06/01/2026
HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a [...]
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
06/01/2026
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the [...]
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
06/01/2026
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the [...]
Fagron announces the completion of Purifarma
06/01/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical [...]
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
January 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
06/01/2026
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland – January 6, 2026 Idorsia Ltd (SIX: IDIA) [...]
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
06/01/2026
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., [...]
Best Turmeric Supplement: Capsules vs Powders vs Drinks – Earth Echo Golden Bliss Consumer Analysis
06/01/2026
January 2026 Wellness Reset: Format Comparison for Morning Routines, Bioavailability, and Daily Ritual Integration Los Angeles, California, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational [...]
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
05/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44 th [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
05/01/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]

Pages